Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients.

6554 Background: Imatinib mesylate (IM) is the first-choice treatment in CML, with excellent response rates. Major and complete molecular responses are the current goals of therapy, but not all pat...